Table 4. Elderly breast cancer characteristics in the literature.
Current study | Evron [17] | Litvak [5] | Brunello [16] | Poltinnikov [18] | Laki [15] | Smith [25] | Yood [9] | |
---|---|---|---|---|---|---|---|---|
N | 134 | 135 | 354 | 260 | 106 | 538 | 56725 | 1837 |
Age | 80+ | 80+ | 70+ | 70+ | 70+ | 70+ | 65+ | 65+ |
Median age | 84 | 83 | N/A | 75.6 (mean) | 76 | N/A | 76 | N/A |
Palpable | 41% | 80% | 46% | N/A | N/A | N/A | N/A | N/A |
T1 | 53% | 90% T1 and T2 | 70% Stage I-II | 53% | 85% | 41% | N/A | 71% |
T2 | 17% | 90% T1 and T2 | 70% Stage I-II | 43% | 15% | 49% | N/A | 29% |
T3 | 4% | N/A | N/A | 3% | 0% | N/A | N/A | N/A |
IDC | 64% | 67% | 71% | 73% | 90% | 78% | N/A | N/A |
ILC | 10% | 11% | 12% | 13% | 10% | 14% | N/A | N/A |
ER positive | 83% | 76% | 45% | 80% | 78% | 84% | N/A | 74% |
Her-2 amplified | 10% | N/A | N/A | N/A | 22% | N/A | N/A | N/A |
Partial mastectomy | 49% | N/A | 47% | 55% | 100%‡ | 72% | 59% | 47% |
Radiation therapy* | 47% | N/A | 45% | 65% | 100%‡ | 100% | 74% | 74% |
Antiestrogen therapy* | 93% | N/A | 67% | N/A | 90% | N/A | N/A | N/A |
Axillary staging performed | 90% | N/A | N/A | 90% | 69% | 89% | N/A | N/A |
Nodal metastases∧ | 25% | 44% | N/A | 36% | 23% | 31% | N/A | N/A |
Median follow-up (months) | 34 | 70 | N/A | 30 | 55 | 91 | N/A | N/A |
Recurrence | 4% | 13% | N/A | N/A | N/A | 9% | N/A | N/A |
Table 4 legend:
N = Number of patients in sample; N/A = not available; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; ER = estrogen receptor.
Calculated as the percentage of patients eligible for therapy, rather than absolute numbers receiving therapy.
Calculated as the percentage of patients undergoing nodal staging who were found to have nodal metastases .
This study examined only women undergoing partial mastectomy with adjuvant radiation therapy.